Can Osteopontin Be Considered a Biomarker for Endometriosis?

In: Revista de Chimie · 2017 · vol. 68(9) , pp. 2132–2134 · doi:10.37358/rc.17.9.5840 · W3007335023
article OA: hybrid CC0
AI-generated summary by claude@2026-06, 2026-06-13

This study found lower serum osteopontin levels in endometriosis patients compared to controls, with levels increasing after progesterone treatment, but the data dispersion makes the association questionable.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis is a multifactorial disease that is manifested by infertility and pelvic pain. The purpose of the study was to evaluate the effect of progesterone treatment on the serum level of osteopontin, a multipotent cytokine, in patients with endometriosis. The study was prospective and we evaluated osteopontin levels that were measured in the serum of 40 patients with endometriosis and 12 healthy women using a standardized Enzyme-Linked Immunosorbent Assay (ELISA) kit. Osteopontin seric levels were lower in endometriosis patients and increased after progesterone treatment. Because of the large dispersion of data even in the control group, we find the association between osteopontin and endometriosis questionable.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK